Global /China /Healthcare /Biotechnology /688247

Sinotherapeutics Inc.

688247

• SSE: 688247 • Delayed

9.30CNY 1.5%

1.37 USD

As of 16 June 2026, Sinotherapeutics Inc. has a market cap of $607.39M USD, ranking #13879 globally and #4256 in China. It ranks #1244 in the Healthcare sector, and #232 in the Biotechnology industry.

Global Rank

13879

Country Rank

4256

Sector Rank

1244

Industry Rank

232

Key Stats

Market Cap

$607.39MUSD

4.11B CNY

Enterprise Value

$494.63MUSD

3.35B CNY

Revenue (TTM)

$65.95MUSD

446.57M CNY

EBITDA (TTM)

$13.79MUSD

93.35M CNY

Net Income (TTM)

$7.01MUSD

47.48M CNY

EBITDA Margin

21%

Profit Margin

11%

PE Ratio

83.3

PS Ratio

9.2

PB Ratio

3.2

EV/EBITDA

35.8

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Ming Jie Guo open_in_new

Employees

312

Founded

2012

Website

sinotph.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.5%	1.6%	-1.9%	-10%	-14%	-4.1%	-6.5%	-43%	-52%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688247 上海宣泰医药科技股份有限公司 Class A ISIN: CNE100005PL9 Shares Out.: Shares Outstanding: 449.004M¹ Shares Float: 95.365M² TV: TradingView: SSE: 688247 SA: Stock Analysis: SHA: 688247 YF: Yahoo Finance: 688247.SS GF: Google Finance: SHA: 688247 BA: Barron's: 688247 MS: Morningstar: XSHG: 688247	9.30 CNY	TV: TradingView: SSE: 688247 SA: Stock Analysis: SHA: 688247 YF: Yahoo Finance: 688247.SS GF: Google Finance: SHA: 688247 BA: Barron's: 688247 MS: Morningstar: XSHG: 688247

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sinotherapeutics Inc.

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.45B 136.71B HKD 3K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 2K%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.01B 54.23B CNY 1K%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.34B 49.69B CNY 1K%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 1K%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 1K%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 30K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 26K%	19.0	United States
argenx SE EBR: ARGX	$47.99B 41.39B EUR 8K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$45.02B 68.19T KRW 7K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.64B 60.27B AUD 7K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.46B 33.71B CHF 7K%	37.2	Switzerland

chevron_leftBack